Harrington Discovery Institute Announces 2022 Grant Funding to 11 Physician-Scientists

Thursday, April 28, 2022

More than 150 drug discovery projects now supported by Harrington Discovery Institute

CLEVELAND Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2022 class of Harrington Scholar-Innovators. The scholar awards will support a diverse set of drug discovery projects including new treatments for pulmonary diseases, COVID-19, multiple cancers, corneal disease, hepatitis, and acquired spinal cord injuries.
Harrington Discovery Institute—part of The Harrington Project for Discovery & Development—was established in 2012 to accelerate the development of new treatments to address major unmet needs in medicine and society. Harrington Scholar-Innovators are accomplished physician-scientists whose research demonstrates innovation, creativity and potential for clinical impact. In addition to grant funding, Harrington provides guidance and oversight in drug development, while intellectual property is retained by the scholar and their institution.
“The 2022 Scholar-Innovator class represents an exciting portfolio of drugs-in-the-making with potential to significantly improve human health. We are honored to support these extraordinary physician-scientists,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute, Robert S. and Sylvia K. Reitman Family Foundation Distinguished Professor of Cardiovascular Innovation and Professor of Medicine and of Biochemistry at University Hospitals and Case Western Reserve University.
The selected scholars have access to several rounds of capital and have the opportunity to qualify for up to a total of $1,100,000 in funding. In addition, scholars have facilitated access to Harrington’s mission-aligned commercial entities, Advent-Harrington Impact Fund and BioMotiv, and to its charitable partner Morgan Stanley GIFT Cures.
Since its founding, Harrington Discovery Institute has supported 162 drugs-in-the-making, 64 institutions, 31 new company launches, 17 clinical candidates and 12 licenses to pharma.
The 2022 Harrington Scholar-Innovator Award recipients, their organizations and fields of research are:  
Burton Dickey, MD – University of Texas MD Anderson Cancer Center
Targeting Syt2 to Prevent Mucus Secretion [in asthma and COPD]
Diana Farmer, MD – University of California, Davis
Engineered Human Stem Cells to treat Spinal Cord Injury
James Hagood, MD – University of North Carolina at Chapel Hill
Thy-1 Mimicry as a Therapeutic Strategy for Pulmonary Fibrosis
Li Lan, MD, PhD – Massachusetts General Hospital
Targeting mRNA Methyltransferase in Cancer
Carolyn Lee, MD, PhD – Stanford University
Drugging Squamous Cell Carcinoma
Michael Lin, MD, PhD – Stanford University
Protease Inhibitors for COVID-19 and Future Coronavirus Diseases
Francis McCormack, MD – University of Cincinnati
An Improved Method of Pleurodesis
David Myung, MD, PhD – Stanford University
Regenerative Therapy for the Cornea
Bernd Schnabl, MD – University of California, San Diego
Bacteriophage Therapy to Treat Alcoholic Hepatitis
Loren Walensky, MD, PhD – Dana-Farber Cancer Institute
Treating Resistant Cancer with Stapled Peptide PROTACs
Hans-Guido Wendel, MD – Memorial Sloan Kettering Cancer Center
Blocking MYC Protein Production in Cancer
                                                                             # # #           

<< Back
  • News Media Access

  • Register
  • Forgot My Password
  • Search:

    Advanced Search

  • Subscribe To Our Latest News

    Subscribe to University Hospitals' RSS Feeds or Email Alerts to get our latest news.

    University Hospitals RSS Feed  University Hospitals Email Alerts
  • Twitter

    Must select a Twitter Account for Rail Gadget in Twitter Tool.

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.